Cadent Therapeutics IPO

Developer of a drug development platform intended to focus on medicines for psychiatric diseases. The company's platform develops small molecule therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders, schizophrenia and other cognitive and neuropsychiatric disorders, enabling patients to cure various neurological diseases.

Register for Details

For more details on financing and valuation for Cadent Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Updated on: Nov 15, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.